Will Celgene's Fast-Growth Streak End In 2013?
Research shows that elite stocks produce annual earnings growth of 25% or more in each of the past three years. Celgene (CELG) met that standard from 2009 through 2012. The Street thinks that streak will end this year when the company earns an estimated $5.66 per share, which would be a 15% increase. Yet, the Street's estimates aren't always right. How much of a beat would it take to hit 25% EPS growth in 2013? Earnings last year were $4.91 per
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here